[ad_1]
"data-reactid =" 11 "> GAITHERSBURG, Md., May 1, 2019 (GLOBE NEWSWIRE) – Novavax, Inc. (NVAX) announced today that Flor M. Muñoz, MD, M.Sc., professor Associate of Pediatrics Baylor Medical College's Virology and Microbiology Molecules and Medical Director, Transplant Infectious Diseases, of Texas Children's Hospital, will present data from the global ResVax ™ Phase 3 clinical trial conducted by the company on the occasion of the 37th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID).) in Ljubljana, Slovenia, 6-11 May 2019. ResVax is the recombinant nanoparticle vaccine , recombinant, fusion virus of the synthesis of respiratory syncytial virus (RSV) of Novavax.
The details are as follows:
| Title of the summary: | PREPARED Phase 3 Study: Efficacy and Safety of an RSV Vaccine Administered to a Pregnant Woman | ||
| Title of the session: | Common Symposium PIDS / ESPID – The future of vaccines (now) | ||
| Session code and track: | ST01; Scientific track | ||
| Location: | Kocka Hall | ||
| Date: | Tuesday, May 7 | ||
| Time: | 10:30 am ET |
<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "You can find the summary of the presentation. right here. In addition, the presentation will be broadcast live. For more information, visit the ESPID meeting website website. "data-reactid =" 15 "> The summary of the presentation can be found right here. In addition, the presentation will be broadcast live. For more information, visit the ESPID meeting website website.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "About ResVax ™ and the Prepare Test"data-reactid =" 16 ">About ResVax ™ and the Prepare Test
<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "ResVax is a recombinant fusion protein RSV (F) nanoparticle vaccine containing aluminum phosphate as an adjuvant.It is being developed to protect infants from RSV through maternal vaccination, which could offer the best method of protection against RSV in infants in the first few months of their life In February 2019, Novavax announced first-line data from Prepare ™, a global phase 3 clinical trial of 4,636 pregnant women, at least 3,000 of whom received the vaccine, and their infants. Prepare is supported by a $ 89.1 million grant from Bill & amp; Melinda Gates Foundation (BMGF). "Data-reactid =" 17 "> ResVax is a recombinant nanoparticle vaccine, consisting of RSV (F) fusion proteins, with aluminum phosphate as adjuvant and is under development to protect Infants from RSV infection through a maternal immunization can offer the best method of protection against RSV in the infant during the first few months of his life. Novavax announced first-line data from Prepare ™, a global phase 3 clinical trial of 4,636 pregnant women, at least 3,000 of whom received the vaccine, and their infants. Prepare benefits from a $ 89.1 million grant from the Bill & Melinda Gates Foundation (BMGF).
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "About Novavax"data-reactid =" 18 ">About Novavax
<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Novavax, Inc. (NVAX) is an advanced biotechnology company developing health worldwide through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax ™, its RSV vaccine for infants via maternal immunization, and NanoFlu ™, its quadrivalent vaccine against influenza nanoparticles. Novavax's patented recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles that meet urgent health needs. "Data-reactid =" 19 "> Novavax, Inc. (NVAX) a leading biotechnology company promoting health worldwide through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases Its two priority programs are ResVax ™, its RSV vaccine for infants via maternal immunization and NanoFlu ™, its quadrivalent nanoparticle for influenza.Novavax's patented recombination technology platform combines power and speed genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles that meet urgent global health needs.
<p class = "canvas-canvas-text canvas Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "For more information, visit the site www.novavax.com& nbsp; and connect with us on Twitter and LinkedIn. "data-reactid =" 20 "> For more information, visit www.novavax.com and contact us at Twitter and LinkedIn.
contacts:
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "investors
Novavax, Inc.
Erika Trahan
[email protected]
240-268-2000 "data-reactid =" 22 ">investors
Novavax, Inc.
Erika Trahan
[email protected]
240-268-2000
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Westwicke
John Woolford
[email protected]
443-213-0506 "data-reactid =" 23 "> Westwicke
John Woolford
[email protected]
443-213-0506
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Media
Sam Brown
Andrea Cohen
[email protected]
917-209-7163 "data-reactid =" 24 ">Media
Sam Brown
Andrea Cohen
[email protected]
917-209-7163
<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "& nbsp;
"data-reactid =" 25 ">
[ad_2]
Source link